Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases Therapy-related myeloid neoplasms (t-MN), including acute myeloid leukemias (t-AML) and myelodysplastic syndromes (t-MDS), indicate myeloid disorders developing in patients treated with radiotherapy and/or chemotherapy for cancer or autoimmune diseases. t-MN represent a unique model of in vivo poison-induced leukemogenesis. It displays a high incidence of monosomies, complex karyotypes and p53 mutations, but other AML-associated mutations, as FLT3, NPM1, CEBPA and TET2 (ten-eleven-translocation 2), are usually rare. [1] [2] [3] In addition, t-MN have been shown to display significant changes in gene expression, including upregulation or downregulation of pathways involved in major cellular processes, which are present long before the development of the t-MN and may be expression of early progenitor damage. 4 These changes are due to the synergistic negative effects of previous treatments, probably in the presence of individual predisposing factors, and finally result into leukemic transformation.
Epigenetic deregulation of gene expression is one of the main pathogenetic processes in AML and MDS. High rates of genespecific methylation have been reported in these diseases, [5] [6] [7] but the underlying mechanisms are poorly understood. The identification of mutations in several genes involved in epigenetic regulation has given new insights. Among these, recurrent somatic mutations of enzymes involved in methylation, including DNMT3A (DNA methyltransferase 3A), IDH1 and IDH2 (isocitrate dehydrogenase 1 and 2), TET2 and EZH2 (enhancer of Accepted article preview online 11 September 2012; advance online publication, 5 October 2012 Letters to the Editor Zeste homolog 2, Drosophila), have been described in about 10-20% of de novo AML.
Defective regulation of proliferation and differentiation in hematologic malignancies may also rely on spliceosomal mutations, which can lead to aberrant alternative splicing and haploinsufficient expression of downstream genes, particularly tumor suppressor genes, causing the neoplastic transformation.
Spliceosome mutations have been identified as leading pathogenetic events in MDS. 8, 9 We were interested in the prevalence of mutations of the epigenetic regulators DNMT3A, IDH1 and IDH2 and of spliceosome enzymes U2AF1 (U2 small nuclear RNA auxiliary factor 1), SF3B1 (splicing factor 3b, subunit 1) and SRSF2 (serine/arginine-rich splicing factor 2) as transforming events in t-MN compared with another type of secondary leukemias, that is, leukemias evolved from chronic myeloproliferative neoplasms (MPN).
We studied 77 patients with a t-MN diagnosed at our institution between October 1998 and February 2012. Clinical characteristics are described in Table 1 . Patients had developed a t-MN at a median of 6.1 years (range 0.7-32 years) from treatment of the primary disease. The most frequent primary neoplasms were lymphoproliferative diseases (32.5%), breast (23%) and genitourinary cancers (17%). Median bone marrow (BM) blasts were 37.5% (range 10-76%), and karyotype was abnormal in 69% of the patients. Sixteen patients with acute leukemia evolved from a MPN were also studied (Supplementary Table 1 ). JAK2 was mutated at V617F in 11 of the 15 MPN patients analyzed (73%). The study has been approved by the institutional review board.
Mononuclear cells (MNC) were separated from BM samples from all patients at the time of t-MN diagnosis, and DNA was extracted using QIAamp DNA Mini Kit (Qiagen srl, Milan, Italy). The following hot-spot mutations were studied on genomic DNA by Sanger sequencing (ABI PRISM 3100; Applied Biosystems/Life technologies, Milan, Italy): IDH1 R132, IDH2 R140 and R172, DNMT3A R882, U2AF1 S34 and R35, SF3B1 exons 13-14 and 15-16, and SRSF2 exon 1. Supplementary Table 1 shows the sequence of oligonucleotides used for sequencing. Associations between the prevalence of mutations and patient characteristics were studied using the Fisher's exact test. The difference in time to leukemic evolution was studied using the log-rank test. Statistical analyses were performed using the Stata 10.0 software (Stata Corp., College Station, TX, USA). All tests were two-sided with a ¼ 0.05.
Looking at epigenetic regulators in t-MN, we found mutually exclusive mutations at IDH1 (3.9%, three R132C) and IDH2 genes (2.6%, one R172K and one R140Q) in five patients (Figure 1 , Supplementary Figures 1 and 2 ). Similar to previous reports on leukemias secondary to MDS and 'therapy-related', 10,11 DNMT3A was only rarely mutated at R882 (5.2%, four R882H). Concurrent R140Q IDH2 and R882H DNMT3A mutations were observed in one patient with a previous breast cancer. Notably, patients with a previous lymphoproliferative disease did not carry mutations in any of the epigenetic genes studied. In t-MN following solid Figure 1 . Distribution of epigenetic and spliceosome mutations in patients with a t-MN, according to the type of previous malignancy. Each box represents a single patient. Black boxes represent mutated patients, whereas empty boxes indicate missing data. All mutation were heterozygous, except for one R882C DNMT3A homozygous mutation in a patient with a previous polycytemia vera. GI, gastro-intestinal; Misc, miscellaneous solid tumors; Oth, autoimmune diseases (three patients) and AML (two patients).
tumors, mutations of epigenetic enzymes were only present in patients with a t-AML (BM-blasts over 20%), but not in t-MDS (7/29 t-AML vs 0/20 t-MDS, P ¼ 0.01). This may be the background for higher methylation levels in t-AML, confirming data on extensive methylation as dominant mechanism in MDS progression to AML. 5, 6 Besides epigenetic mechanisms, mammalian cells control gene expression by the spliceosome machinery, whose mutations have been recently shown to have a role in myeloid diseases. 8, 9 To our knowledge, this is the first study on spliceosome mutations in t-MN. We did not find any U2AF1 S34 or R35 mutations in any of our patients (Figure 1 ). The SF3B1 gene was rarely mutated with only 4% (3/74 patients) carriers of the recurrent K700E mutation at exons [15] [16] and no mutations at exons 13-14. The P95 amino-acid residue in exon 1 of the SRSF2 gene was the most frequent mutation hot-spot (8/77 patients, 10.4%, 6 P95H and 2 P95R mutations). One of the P95R-mutated patient contextually had a P96 insertion. SRSF2 mutation frequency was significantly higher in leukemias following genito-urinary tumors (4/13, 30.8%), compared with other t-MN (4/64, 6.2%, P ¼ 0.02). In t-MN following lymphoproliferative disorders, there was only one SRSF2 mutation (1/25, 4%).
We found the highest frequency of mutations of epigenetic regulators and splicing enzymes in acute leukemias evolved from MPN. Indeed, they were significantly more frequently mutated for IDH1/IDH2 (5/15, 33%) and SRSF2 (5/15, 33%), when compared with those secondary to other primary diseases (6.6%, P ¼ 0.01 and 10.4%, P ¼ 0.03, respectively) ( Figure 1, Supplementary  Table 1 ). Concurrent R140Q IDH2 and R882H DNMT3A mutations were observed in two patients. Our findings are substantially aligned with previous data on large patient cohorts of AML derived from MPN, where mutations of IDH1/IDH2 and SRSF2 have been reported in 21.5% and 18.9% of the patients, respectively. 12, 13 This proportion is significantly higher than that of patients with chronic phase MPN, where they are present in less than 5% of cases. 8, 12 Zhang et al. 13 also showed acquisition of TP53 and K-Ras, but not SRSF2, mutations during leukemic evolution in 17 patients with paired samples from the previous chronic phase MPN. We examined BM samples from the primary MPN phase in six patients. Our data are not sufficient to determine whether leukemic transformation is associated to the acquisition of the mutations, as we observed the same pattern of mutations in all paired MPN and leukemic samples studied (five patients remained wild-type for all genes and one patient had a stable IDH2 mutation). Epigenetic and splicing mutations may arise in early MPN leukemic progenitors. In this line, leukemic CD34 þ cells separated by immunomagnetic selection (CD34 MicroBead Kit human, MACS Miltenyi Biotec, Bergisch Gladbach, Germany) from peripheral blood-MNC at the time of leukemic evolution in eight patients displayed the same mutation pattern as the more mature CD34-negative counterpart.
In our patients, IDH1/2, DNMT3A and SRSF2 mutations were exclusive of patients with previous MPN older than 60 years (Supplementary Table 2 ). They developed acute leukemia at a median of 4.7 years (range 1.4-15.5) from the primary MPN diagnosis (eight polycythemia vera, six idiopathic myelofibrosis, one essential thrombocythemia and one hyperosinophilic syndrome). The SRSF2 mutation was associated to significantly faster leukemic transformation (median: 40 versus vs 70 months, P ¼ 0.04) (Supplementary Figure 3) . In this line, Zhang et al. 13 recently reported that SRSF2 mutations resulted associated with poor survival in 53 MPN patients who underwent leukemic transformation. All our patients had received cytotoxic treatment before leukemic evolution of MPN, consisting of hydroxyurea (HU) alone in 10 cases and combined to radiotherapy or other cytotoxic agents in 5 patients (Supplementary Table 2 ). Prolonged administration of HU alone in MPN has not been associated to increased leukemogenic risk.
14,15 Indeed, we found most of mutations in patients treated with HU alone (Supplementary Table 2) , who also had a high incidence of chromosomal abnormalities (6 of 10 patients, 60%), consisting of isolated deletion of chromosome 5 or 7 in 2 patients and a complex karyotype in 4 patients (including MLL rearrangement in 1 and chromosome 5 and/or 7 deletion in 2 patients). These findings seem to argue against a natural leukemic evolution of the MPN independent of HU treatment, even though the small number of cases is not sufficient to draw definite conclusions. 14, 15 In summary, the incidence of mutations in epigenetic and spliceosome genes varies in t-MN according to the type of previous malignancy. In fact, they are rare or absent in patients with a previous lymphoproliferative disease, but more frequent in t-MN following solid tumors and in leukemias evolved from a previous MPN. Our study indicates the hot-spot mutation at P95 in the spliceosome enzyme SRSF2 as a new candidate for secondary leukemogenesis, not only in MPN, where it may accelerate leukemic transformation, but also in t-MN following solid tumors. Further studies are needed to address the pathogenetic mechanisms by which this mutation contributes to secondary leukemogenesis.
